KR20220149669A - 엔시펜트린 및 글리코피롤레이트를 포함하는 액상 약제학적 조성물 - Google Patents

엔시펜트린 및 글리코피롤레이트를 포함하는 액상 약제학적 조성물 Download PDF

Info

Publication number
KR20220149669A
KR20220149669A KR1020227029927A KR20227029927A KR20220149669A KR 20220149669 A KR20220149669 A KR 20220149669A KR 1020227029927 A KR1020227029927 A KR 1020227029927A KR 20227029927 A KR20227029927 A KR 20227029927A KR 20220149669 A KR20220149669 A KR 20220149669A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
glycopyrrolate
composition according
encifenthrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227029927A
Other languages
English (en)
Korean (ko)
Inventor
피터 라이오넬 스파르고
필립 앤드류 헤이우드
에드워드 제임스 프렌치
Original Assignee
베로나 파마 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베로나 파마 피엘씨 filed Critical 베로나 파마 피엘씨
Publication of KR20220149669A publication Critical patent/KR20220149669A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227029927A 2020-02-27 2021-02-26 엔시펜트린 및 글리코피롤레이트를 포함하는 액상 약제학적 조성물 Pending KR20220149669A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2002786.8 2020-02-27
GBGB2002786.8A GB202002786D0 (en) 2020-02-27 2020-02-27 Liquid pharmaceutical composition
PCT/GB2021/050496 WO2021171034A1 (en) 2020-02-27 2021-02-26 Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate

Publications (1)

Publication Number Publication Date
KR20220149669A true KR20220149669A (ko) 2022-11-08

Family

ID=70278709

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227029927A Pending KR20220149669A (ko) 2020-02-27 2021-02-26 엔시펜트린 및 글리코피롤레이트를 포함하는 액상 약제학적 조성물

Country Status (25)

Country Link
US (1) US20230112220A1 (OSRAM)
EP (2) EP4306129A3 (OSRAM)
JP (2) JP7781762B2 (OSRAM)
KR (1) KR20220149669A (OSRAM)
CN (1) CN115279343A (OSRAM)
AU (1) AU2021227456A1 (OSRAM)
BR (1) BR112022016015A2 (OSRAM)
CA (1) CA3166952A1 (OSRAM)
DK (1) DK4110292T3 (OSRAM)
ES (1) ES2970571T3 (OSRAM)
FI (1) FI4110292T3 (OSRAM)
GB (1) GB202002786D0 (OSRAM)
HR (1) HRP20240288T1 (OSRAM)
HU (1) HUE065531T2 (OSRAM)
IL (1) IL295442A (OSRAM)
LT (1) LT4110292T (OSRAM)
MX (1) MX2022010014A (OSRAM)
PH (1) PH12022552278A1 (OSRAM)
PL (1) PL4110292T3 (OSRAM)
PT (1) PT4110292T (OSRAM)
RS (1) RS65330B1 (OSRAM)
SI (1) SI4110292T1 (OSRAM)
SM (1) SMT202400076T1 (OSRAM)
WO (1) WO2021171034A1 (OSRAM)
ZA (1) ZA202208763B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
EP4609864A4 (en) * 2022-10-28 2026-02-18 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING AN ISOQUINOLINONE COMPOUND AND RELATED PREPARATION PROCESS
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368413C (en) 1999-03-31 2008-07-29 Verona Pharma Plc Derivatives of pyrimido[6,1-a]isoquinolin-4-one
NZ587561A (en) * 2008-02-26 2012-10-26 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
SI2968313T1 (en) 2013-03-15 2018-05-31 Verona Pharma Plc Combination of medicines
PT3332767T (pt) * 2014-09-15 2019-06-27 Verona Pharma Plc Formulação por inalação líquida compreendendo rpl554

Also Published As

Publication number Publication date
ES2970571T3 (es) 2024-05-29
JP2026035711A (ja) 2026-03-04
CN115279343A (zh) 2022-11-01
SI4110292T1 (sl) 2024-03-29
FI4110292T3 (fi) 2024-03-01
LT4110292T (lt) 2024-02-12
GB202002786D0 (en) 2020-04-15
EP4110292A1 (en) 2023-01-04
MX2022010014A (es) 2022-10-18
JP7781762B2 (ja) 2025-12-08
SMT202400076T1 (it) 2024-03-13
EP4110292B1 (en) 2024-01-10
IL295442A (en) 2022-10-01
AU2021227456A1 (en) 2022-09-08
EP4306129A3 (en) 2024-04-17
DK4110292T3 (da) 2024-02-19
BR112022016015A2 (pt) 2022-10-11
RS65330B1 (sr) 2024-04-30
PH12022552278A1 (en) 2024-03-04
HUE065531T2 (hu) 2024-05-28
JP2023516630A (ja) 2023-04-20
WO2021171034A1 (en) 2021-09-02
PL4110292T3 (pl) 2024-05-20
US20230112220A1 (en) 2023-04-13
CA3166952A1 (en) 2021-09-02
ZA202208763B (en) 2024-01-31
HRP20240288T1 (hr) 2024-05-24
PT4110292T (pt) 2024-01-31
EP4306129A2 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
AU2020203081B2 (en) Liquid inhalation formulation comprising RPL554
EP4110292B1 (en) Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate
HK1249415A1 (en) Liquid inhalation formulation comprising rpl554
AU2020328223A1 (en) Pharmaeutical composition comprising ensifentrine
WO2020141472A1 (en) Nebulization composition comprising tiotropium and indacaterol
RU2831388C1 (ru) Жидкая фармацевтическая композиция, содержащая энсифентрин и гликопирролат
HK40097440A (en) Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate
HK40077584B (en) Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate
HK40077584A (en) Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate
HK1233919B (en) Liquid inhalation formulation comprising rpl554
HK1233919A1 (en) Liquid inhalation formulation comprising rpl554

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902